New York, NY -- (SBWIRE) -- 02/01/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: Questcor Pharmaceuticals Inc (NASDAQ:QCOR), XenoPort, Inc. (NASDAQ:XNPT), Incyte Corporation (NASDAQ:INCY), Enanta Pharmaceuticals Inc (NASDAQ:ENTA)
Questcor Pharmaceuticals Inc (NASDAQ:QCOR) declined -0.06%, trading on 1.64 million shares, to end the trade at $67.01. If we look at its trading history of the past 52 weeks, the share price suffered a low of $24.75 and was moved to the maximum level of $74.76. The stock changed hands in a range of $65.27 to $67.81, bringing its market capitalization to about $4.07 billion. Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. The Company is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.
Will QCOR Bounce Back After yesterday’s Sharp Sell off? Find Out Here
XenoPort, Inc. (NASDAQ:XNPT) declined -4.96%, to complete the trading session at $5.75, with a total volume of 1.63 million shares. The stock, on average, trades on a volume of 832,214 shares. In the past 52 weeks, the share price has not declined below $4.24 and above $9.11. It floated in a range of $5.74 to $6.06 during the last trading session, with a beta value of 0.40. Its market capitalization now moved to about $343.46 million. XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally for the treatment of neurological disorders. The product candidates are prodrugs that are created by modifying the chemical structure of marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and/or metabolism of the parent drug.
Is it the Right to Grab XNPT after the Recent Slump? Get Free Trend Analysis Here
Incyte Corporation (NASDAQ:INCY) recorded a fall of -1.40% and was in a range of $64.88-$66.21 before closing at $65.52. The share price hit its 52-week low of $17.44 and $67.45 was the best price. The stock completed the day with a total volume of 1.59 million shares, versus an average volume of 1.62 million shares. Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.
Will INCY Reach the Bottom after Yesterday’s Correction? Find Out Here
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) added 13.36% yesterday, bringing its market capitalization around $657.04 million. The total number of shares that changed hands during the session was 1.59 million shares, as compared to average trading volume of 191,987 shares. The share price, after opening at $37.00, made a high of $38.22 and hovered above $35.39 to end the day at $36.58. Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.
Will ENTA Continue To Move Higher? Find Out Here
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)